|Application No.||Application Title||Issue Date|
|20140051723||DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF|
The subject invention provides deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, its salts and uses....
|20140051724||MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS|
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods o...
|20140045889||Combination Drug Containing Probucol and a Tetrazolyalkoxy-Dihydrocarbostyril Derivative With Superoxide Supressant Effects|
This invention relates to a combination drug comprising a combination of a tetrazolylalkoxy-dihydrocarbostyril derivative of the formula:
wherein R is cycloalkyl, A is lower alkylene, and the bond between 3- ...
|20140045886||LAQUINIMOD FOR TREATMENT OF GABA MEDIATED DISORDERS|
This invention provides a method of treating a subject suffering from a GABA related disorder comprising periodically administering to the subject an effective amount of laquinimod or pharmaceutically acceptable salt thereof in an amount effective to treat the subject....
|20140045885||Decoquinate, 4-hydroxyquinolones and napthoquinones combined with levamisole, Imidazothiazole, for the prevention and treatment of sarcocystosis and equine protozoal myeloencephalitis caused by Sarcocystis and Neospora and other apicomplexan protozoans.|
Apicomplexan parasites that infect horses such as Sarcocystis sp., Sarcocystis neurona and Neospora hughesi may be killed with decoquinate, a 4-hydroxyquinolone and/or a naphthoquinone and enhanced effects for treatment of animal disease are seen wi...
|20140045888||COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY|
Compounds of formula I:
or formula II:
|20140045887||LAQUINIMOD FOR TREATMENT OF CANNABINOID RECEPTOR TYPE 1(CB1) MEDIATED DISORDERS|
This invention provides a method of treating a human subject suffering from a CB1 receptor related disorder comprising periodically administering to the subject an effective amount of laquinimod or pharmaceutically acceptable salt thereof in an amount effective to treat...
|20140038883||NOVEL AZACOUMARIN DERIVATIVES HAVING MDR PUMP INHIBITING ACTIVITY|
The present invention relates to compounds of formula (I), where R1 and R2, identical or different, are each independently a hydrogen atom or a non-substituted or substituted (C1-C12) alkyl group; R3 is a hydrogen a...
|20140039005||NOVEL REBAMIPIDE COMPLEXES AND COCRYSTALS|
New rebamipide complexes and new rebamipide cocrystals are disclosed, specifically a 1:1 rebamipide nicotinamide complex, a 1:1 rebamipide nicotinamide cocrystal, a 1:1 rebamipide 2,4-dihydroxybenzolc acid complex, and a 1:1 rebamipide 2,4-dihydroxybenzoic acid cocrysta...
|20140038927||COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS|
The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Al...
|20140038928||5-(2--1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES|
The present invention provides a compound which is a hydroxyquinolinone derivative of formula (I),
in the form of a racemate, a stereoisomer or a mixture of stereoisomers, or a pharmaceutically acceptable sal...
|20140037719||STABILIZED PHARMACEUTICAL FORMULATIONS OF A POTENT HCV INHIBITOR|
Described are various methods for stabilizing pharmaceutical formulations of a specific Hepatitis C Viral (HCV) inhibitor against the formation of a particular genotoxic degradation product. Such methods include temperature control, moisture control, excipient control, ...
|20140038944||FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS|
A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof,
|20140030223||INHIBITORS OF FLAVIVIRIDAE VIRUSES|
Provided are compounds of Formula I:
and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, ...
|20140024677||METHODS FOR INDUCING MITOCHONDRIAL BIOGENESIS|
Methods and compositions for inducing mitochondrial biogenesis are provided. In some aspects, methods for the treatment of diseases such as acute kidney disease (AKI) or a muscle wasting disease by administering tomoxetine, nisoxetine, fenoterol, formoterol, or procater...
|20140024678||STABLE LAQUINIMOD PREPARATIONS|
The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5- chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-ph...
|20140018385||Identification Of PCNA Targeting Compounds For Cancer Therapy And PCNA Function Regulation|
Pharmaceutical compositions and methods for inhibiting cell growth, modulating function of PCNA, treating prostate cancer, and enhancing PCNA trimer formation are disclosed. The methods include administering an effective amount of a compound of Formula (I), Formula (II)...
|20140018386||LAQUINIMOD FORMULATIONS WITHOUT ALKALIZING AGENT|
The subject invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler, and an amount of a lubricant, wherein the stable pharmaceutical composition is free of an alkalizing agent or an oxidat...
|20140018384||QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE|
There is provided compounds of formula I, wherein X1 to X4, R1 to R4, Y1, Y2 and L are as defined in the description, and pharmaceutically-acceptable salts thereof, which may be useful in the treatment an...
|20140017226||TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FAMPRIDINE|
This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject fampridine as an add-on therapy to or in combination with laquinimod. This invention also provid...
|20140018365||PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS|
The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfa...
|20140018387||OINTMENT WITH EXCELLENT FORMULATION STABILITY|
Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene•3/2 hydrate, 3...
|20140010882||PHARMACEUTICAL COMPOSITION FOR TREATING A DISEASE IN THE ORAL CAVITY COMPRISING REBAMIPIDE|
The present invention is directed to a pharmaceutical composition comprising rebamipide having a mean particle size of less than 500 nm, a dispersing agent, and a viscosity enhancing agent wherein the viscosity enhancing agent has no aggregative action for the rebamipid...
|20130343993||RADIOLABELED 5-HT6 LIGANDS|
Compounds of formula (I) are disclosed
Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by 5-HT6 receptor ligands. Radiolabeled compounds of form...
|20130345257||COMPOSITION FOR LUPUS NEPHRITIS AND METHODS OF MAKING AND USING THE SAME|
Provided herein are compositions and methods associated with the prevention and treatment of lupus nephritis. In particular, provided herein is a method for delaying onset of active lupus nephritis in a subject at risk for developing active lupus nephritis, comprising p...
|20130344165||JAB1 INHIBITORY COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO|
This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subje...
The subject invention provides pharmaceutical compositions containing laquinimod or a pharmaceutically acceptable salt thereof, an isolated compound of N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxa...
|20130344061||TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS|
Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions)....
The present invention relates to compounds of the formula (I),
salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds as act...
|20130338188||PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF|
The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations the...
|20130338189||CRYSTAL OF ANTI-BACTERIAL COMPOUND|
It is intended to provide a salt of a compound and crystals thereof useful as a therapeutic and/or preventive agent for infectious diseases which has wide and excellent antibacterial activity and has excellent safety.
|20130338154||MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION|
Pyrrole compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compo...
|20130338151||FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS|
The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses o...
|20130331412||Pharmaceutical Compositions and Administrations Thereof|
The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patie...
|20130331364||DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY|
This invention relates to a compound of formula I:
|20130324574||TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD|
Disclosed is a method for treating an ocular inflammatory disease (OID), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceuti...
|20130324570||INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS|
The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formulas (I)-(XXVI) as disclosed herein to inhibit tra...
|20130324521||IMPLANT FOR TREATING OR PREVENTING AN ANEURYSM|
A medical product (1) introducible into a blood vessel (2) comprising a drug (3) for the treatment of an aneurysm and of arteriosclerotic diseases. The drug (3) is a farnesyltransferase inhibitor....
|20130317061||Crystalline Salts of a Potent HCV Inhibitor|
This invention relates to novel tris(hydroxymethyl)aminomethane, choline and N-methyl-D-glucamine salt forms of the following Compound (1) and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (...
|20130317060||Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide|
The present invention relates to solid state forms of N—[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith....